Skip to main content

Genetic Syndrome clinical trials at UC Health
1 research study open to new patients

  • EDS in Ataxia Telangiectasia Patients

    open to eligible people ages 6 years and up

    This is an international, multi-center, one-year, randomized, prospective, double-blind, placebo-controlled, phase III study, designed to assess the effect of two non-overlapping dose ranges of EDS EP, administered by IV infusion once per month, on neurological symptoms of patients with Ataxia Telangiectasia.

    at UCLA

Last updated: